本报讯(记者袁传玺) 日前，礼来制药旗下穆峰达(替尔泊肽注射液多剂量预装笔)在京东健康股份有限公司(以下简称"京东健 康")线上首发。穆峰达作为全球首个且目前唯一获批用于2型糖尿病和长期体重管理的GIP/GLP-1受体激 动剂，自上市以来便以其独特的双重作用机制和显著的疗效，赢得了广大患者的信赖与好评。此次替尔 泊肽注射液多剂量预装笔，是礼来制药推出的新型注射装置，将为患者带来全新的选择。 京东健康相关负责人表示："我们非常高兴能够与礼来制药合作，率先引入穆峰达多剂量预装笔。这款 改进剂型将在京东买药秒送独家首发，并同步在京东买药上线，给患者带来更加方便、快捷的购买体 验。未来，我们将继续与全球药企紧密合作，共同推动新特药的普及和可及性，为更多患者提供精准、 高效的治疗方案。" 随着穆峰达多剂量预装笔在京东健康平台的线上首发，相信将有更多2型糖尿病和肥胖患者从中受益， 实现更加健康、美好的生活。 此次，礼来制药改进了穆峰达的注射装置。穆峰达(替尔泊肽注射液多剂量预装笔)采用了创新的"4剂集 成"设计，每支笔包含四个固定剂量，每周使用一个剂量，即可满足患者一个月的治疗需求。这一设计 不仅简化了用药流程，减少了患 ...

Group 1 - U.S. stock index futures are all down, with Nasdaq futures down 0.51%, S&P 500 futures down 0.49%, and Dow futures down 0.62% [1] - European stock indices show mixed results, with Germany's DAX down 1.02%, UK's FTSE 100 up 0.17%, France's CAC down 0.48%, and the Euro Stoxx 50 down 0.77% [1] - Wells Fargo indicates that tariff pressures will prevent U.S. stocks from reaching new highs this year, favoring large and mid-cap stocks [1] - Fitch has downgraded the global oil and gas industry's outlook to "deteriorating" due to lower-than-expected oil demand growth and rising supply [1] Group 2 - Oracle reported fourth-quarter revenue of $15.9 billion, with adjusted earnings per share of $1.70, both exceeding expectations [1] - BioNTech has agreed to acquire CureVac for approximately $1.25 billion to develop its oncology business [1] - Micron Technology announced it has delivered samples of 36GB HBM4 with 12 layers to several major customers [1]